Research Radartracking 0 published studies · 2 cancer pages · updated Jun 2026Open the Research Map →

CoQ10 (Ubiquinol)

Mitochondrial cofactor that boosts energy/antioxidants, protects heart in cardiotoxic therapies; preclinical apoptosis/anti-growth signals.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Human studies support cardioprotection/biomarker changes; antitumor effects mainly preclinical.UbiquinolCoenzyme Q10Ubidecarenone

Forms: CoQ10 capsules (100–300 mg)

Educational only, not medical advice. OncoForge makes no claim that CoQ10 (Ubiquinol) treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

CoQ10 supports mitochondrial energy and helps protect the heart during cardiotoxic therapies; small trials and meta-analyses show benefit signals. In lab models it can push cancer cells toward apoptosis and tone down ERK/AKT/VEGF, but clinical antitumor data are early.

Evidence at a glance

Tier 3 · early humanBreast (HER2+)Various (anthracycline-treated)Preclinical models

Human cardioprotection strong; antitumor preclinical with early adjunct signals.

How it may work

CoQ10, an electron carrier in the mitochondrial electron transport chain (ETC), enhances ATP production and reduces oxidative stress via antioxidant properties. It mitigates anthracycline- and HER2-therapy–related cardiotoxicity by stabilizing mitochondrial membranes. CoQ10 also induces apoptosis in cancer cells and downregulates pro-growth signaling (e.g., ERK/Akt), while reducing angiogenic factors (e.g., VEGF) and inflammatory signaling.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

  • Mitochondrial ETC / ATP Production↑
  • Oxidative Stress↓Antioxidant properties
  • Cardiotoxicity (Anthracycline/HER2)↓Membrane stabilization
  • Apoptosis↑In cancer cells
  • ERK/Akt Signaling↓
  • VEGF / Angiogenesis↓
Mito SupportCardio-ProtectApoptosis ↑

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Overlapping mechanisms

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories
Gi Upset MildAnticoagulant CautionHypotension Risk MildPregnancy Avoid
Potential interactions
  • Warfarin / AnticoagulantsMonitorModerateTheoreticalMay decrease anticoagulant effect.
  • TKIs (e.g., imatinib)SeparateMinorTheoreticalPossible interaction; separate dosing if advised.
  • Anthracyclines / HER2 therapiesConsiderBeneficialTheoreticalCardioprotection; preclinical synergies.

Timing

References

Research

No published studies for CoQ10 (Ubiquinol) yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of CoQ10 (Ubiquinol) depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 100–300 mg (po) Once or divided daily. Oncology adjunct: 200–300 mg/day ubiquinol form for cardioprotection/antitumor support, based on trials/meta-analyses., No Rx required. Ubiquinol preferred for bioavailability; take with fatty meal. Clinician oversight for oncology; monitor LFTs if high-dose..

Trials studying CoQ10 (Ubiquinol)

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar